Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Jaguar Animal Health, Inc. (JAGX) Starts Presentation at Marcum MicroCap Conference

Jaguar Animal Health (NASDAQ: JAGX) is an animal health company focused on the development and commercialization of first-in-class gastrointestinal products for companion and production animals, foals, and high-value horses. The company’s lead prescription drug product candidate, Canalevia, is intended for the treatment of various forms of diarrhea in dogs. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species, formulations of SB-300 in horses, and Canalevia for cats and dogs. For more information, visit the company’s website at www.jaguaranimalhealth.com

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.